Patents by Inventor Yarlagadda S. Babu

Yarlagadda S. Babu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10022375
    Abstract: The present invention is directed to methods and compositions for inhibition of viral nucleic acid polymerases, such as RNA and DNA polymerases, and methods and compositions that are useful for treating viral infections in subjects. The methods comprise administering to the subject a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or hydrate thereof, or a composition comprising a compound of formula I, or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier. The composition or method may optionally comprise one or more additional anti-viral agents.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: July 17, 2018
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Shanta Bantia, Pravin L. Kotian, Yarlagadda S. Babu
  • Publication number: 20180015063
    Abstract: The invention provides unit dosage forms, kits, and methods useful for treating viral infections.
    Type: Application
    Filed: September 25, 2017
    Publication date: January 18, 2018
    Inventors: Yarlagadda S BABU, Pooran Chand, Shanta Bantia, Shane Arnold, John Michael Kilpatrick
  • Patent number: 9770427
    Abstract: The invention provides unit dosage forms, kits, and methods and useful for treating viral infections.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: September 26, 2017
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Yarlagadda S Babu, Pooran Chand, Shanta Bantia, Shane Arnold, John Michael Kilpatrick
  • Publication number: 20170266172
    Abstract: Use of a compound of formula (I): wherein A, X, Y, R1 and R2 as defined herein, in treating hereditary angioedema is disclosed. A composition containing the compounds, a polar organic solvent or a mixture thereof; and optionally a co-solvent, is also disclosed.
    Type: Application
    Filed: August 24, 2015
    Publication date: September 21, 2017
    Inventors: Yarlagadda S BABU, Vivekanand P KAMATH, Walter GOWAN
  • Publication number: 20170267681
    Abstract: Disclosed are compounds comprising an azasugar attached to a heterocyclic base, including pharmaceutically acceptable salts thereof, suitable for use in inhibiting viral RNA polymerase activity or viral replication, and treating viral infections. The compounds are characterized, in part, by favorable pharmacokinetics for the active pharmaceutical ingredient, particularly in conjunction with enteral administration, including, in particular, oral administration. Also disclosed are pharmaceutical compositions comprising one or more compounds mentioned above, or pharmaceutically acceptable salts thereof, as well as methods for preparing same. Also provided are methods for inhibiting viral RNA polymerase activity, viral replication, and treating viral infections.
    Type: Application
    Filed: March 31, 2017
    Publication date: September 21, 2017
    Inventors: Yarlagadda S. Babu, Pravin L. Kotian, Shanta Bantia, Minwan Wu, V. S. Kumar
  • Publication number: 20170137429
    Abstract: Disclosed are novel compounds comprising an imino-ribose derivative covalently linked to a carbocycle or heterocycle. Pharmaceutical compositions comprising the compounds of the invention are also described. Methods of inhibition, treatment and/or suppression of viral infections with the compounds of the invention are also described. The compositions or methods may optionally comprise one or more additional anti-viral agents.
    Type: Application
    Filed: November 21, 2016
    Publication date: May 18, 2017
    Inventors: William P. Sheridan, Shanta Bantia, Pravin L. Kotian, Yarlagadda S. Babu
  • Publication number: 20170128454
    Abstract: Provided are compounds of Formula I: as described herein. Compounds of Formula I are useful in methods of inhibiting viral RNA polymerase activity and viral replication. Also provided are pharmaceutical compositions comprising compounds of Formula I, as well as methods of treating viral infections using compounds of Formula I.
    Type: Application
    Filed: January 20, 2017
    Publication date: May 11, 2017
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu
  • Patent number: 9580428
    Abstract: Provided are compounds of Formula I: as described herein. Compounds of Formula I are useful in methods of inhibiting viral RNA polymerase activity and viral replication. Also provided are pharmaceutical compositions comprising compounds of Formula I, as well as methods of treating viral infections using compounds of Formula I.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: February 28, 2017
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu
  • Publication number: 20170042901
    Abstract: The present invention is directed to methods and compositions for inhibition of viral nucleic acid polymerases, such as RNA and DNA polymerases, and methods and compositions that are useful for treating viral infections in subjects. The methods comprise administering to the subject a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or hydrate thereof, or a composition comprising a compound of formula I, or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier. The composition or method may optionally comprise one or more additional anti-viral agents.
    Type: Application
    Filed: October 28, 2016
    Publication date: February 16, 2017
    Inventors: Shanta Bantia, Pravin L. Kotian, Yarlagadda S. Babu
  • Patent number: 9499554
    Abstract: Disclosed are novel compounds comprising an imino-ribose derivative covalently linked to a carbocycle or heterocycle. Pharmaceutical compositions comprising the compounds of the invention are also described. Methods of inhibition, treatment and/or suppression of viral infections with the compounds of the invention are also described. The compositions or methods may optionally comprise one or more additional anti-viral agents.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: November 22, 2016
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: William P. Sheridan, Shanta Bantia, Pravin L. Kotian, Yarlagadda S. Babu
  • Patent number: 9492452
    Abstract: The present invention is directed to methods and compositions for inhibition of viral nucleic acid polymerases, such as RNA and DNA polymerases, and methods and compositions that are useful for treating viral infections in subjects. The methods comprise administering to the subject a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or hydrate thereof, or a composition comprising a compound of formula I, or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier. The composition or method may optionally comprise one or more additional anti-viral agents.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: November 15, 2016
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Shanta Bantia, Pravin L. Kotian, Yarlagadda S. Babu
  • Publication number: 20160096842
    Abstract: Disclosed are novel compounds comprising an imino-ribose derivative covalently linked to a carbocycle or heterocycle. Pharmaceutical compositions comprising the compounds of the invention are also described. Methods of inhibition, treatment and/or suppression of viral infections with the compounds of the invention are also described. The compositions or methods may optionally comprise one or more additional anti-viral agents.
    Type: Application
    Filed: May 14, 2014
    Publication date: April 7, 2016
    Inventors: William P. Sheridan, Shanta Bantia, Pravin L. Kotian, Yarlagadda S. Babu
  • Publication number: 20150291596
    Abstract: Disclosed are compounds comprising an azasugar attached to a heterocyclic base, including pharmaceutically acceptable salts thereof, suitable for use in inhibiting viral RNA polymerase activity or viral replication, and treating viral infections. The compounds are characterized, in part, by favorable pharmacokinetics for the active pharmaceutical ingredient, particularly in conjunction with enteral administration, including, in particular, oral administration. Also disclosed are pharmaceutical compositions comprising one or more compounds mentioned above, or pharmaceutically acceptable salts thereof, as well as methods for preparing same. Also provided are methods for inhibiting viral RNA polymerase activity, viral replication, and treating viral infections.
    Type: Application
    Filed: November 18, 2013
    Publication date: October 15, 2015
    Inventors: Yarlagadda S. Babu, Pravin L. Kotian, Shanta Bantia, Minwan Wu, V. Satish Kumar
  • Publication number: 20150191472
    Abstract: Provided are compounds of Formula I: as described herein. Compounds of Formula I are useful in methods of inhibiting viral RNA polymerase activity and viral replication. Also provided are pharmaceutical compositions comprising compounds of Formula I, as well as methods of treating viral infections using compounds of Formula I.
    Type: Application
    Filed: April 17, 2013
    Publication date: July 9, 2015
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu
  • Publication number: 20150051230
    Abstract: The present invention is directed to methods and compositions for inhibition of viral nucleic acid polymerases, such as RNA and DNA polymerases, and methods and compositions that are useful for treating viral infections in subjects. The methods comprise administering to the subject a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or hydrate thereof, or a composition comprising a compound of formula I, or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier. The composition or method may optionally comprise one or more additional anti-viral agents.
    Type: Application
    Filed: November 3, 2014
    Publication date: February 19, 2015
    Inventors: Shanta Bantia, Pravin L. Kotian, Yarlagadda S. Babu
  • Publication number: 20140309301
    Abstract: The invention provides unit dosage forms, kits, and methods and useful for treating viral infections.
    Type: Application
    Filed: June 24, 2014
    Publication date: October 16, 2014
    Inventors: Yarlagadda S. Babu, Pooran Chand, Shanta Bantia, Shane Arnold, John Michael Kilpatrick
  • Publication number: 20140178372
    Abstract: The present application relates to treatment of hematologic cancers, which treatments can include, e.g., administration of a purine nucleoside phosphorylase (PNP) inhibitor, an alkylating agent and/or an anti-CD20 agent, and related compositions and kits.
    Type: Application
    Filed: February 26, 2014
    Publication date: June 26, 2014
    Applicant: BIOCRYST PHARMACEUTICALS, INC.
    Inventors: Shanta BANTIA, Philip BREITFELD, Yarlagadda S. BABU
  • Publication number: 20130331404
    Abstract: The present invention is directed to methods and compositions for inhibition of viral nucleic acid polymerases, such as RNA and DNA polymerases, and methods and compositions that are useful for treating viral infections in subjects. The methods comprise administering to the subject a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or hydrate thereof, or a composition comprising a compound of formula I, or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier. The composition or method may optionally comprise one or more additional anti-viral agents.
    Type: Application
    Filed: October 14, 2011
    Publication date: December 12, 2013
    Applicant: BioCryst Pharmaceuticals, Inc.
    Inventors: Shanta Bantia, Pravin L. Kotian, Yarlagadda S. Babu
  • Patent number: 8440813
    Abstract: The invention provides compounds of Formula (I), as described herein, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates that are useful for preparing the compounds. The compounds of Formula (I) are useful as anti-viral agents and/or as anti-cancer agents.
    Type: Grant
    Filed: January 11, 2008
    Date of Patent: May 14, 2013
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Yarlagadda S. Babu, Pooran Chand, V. Satish Kumar, Pravin L. Kotian, Minwan Wu
  • Publication number: 20130078218
    Abstract: The invention provides methods for treating hepatitis C viral infections and related viral infections, as well as compounds and compositions that are useful for treating such infections.
    Type: Application
    Filed: March 26, 2012
    Publication date: March 28, 2013
    Inventors: Yarlagadda S. Babu, Pooran Chand, Minwan Wu, Pravin L. Kotian, V. Satish Kumar, Tsu-Hsing Lin, Yahya El-Kattan, Ajit K. Ghosh